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Renal Disease in Hematological Malignancies
Ibrahiem Saeed Abdul-Rahman
Hematological malignancies can affect the kidneys in different ways. There may be direct invasion by the tumor 
cells, or the malignancy may act indirectly via immunologically mediated mechanisms. Primary renal lymphoma 
(PRL) without evidence of extrarenal spread has also been reported. The existence of this entity, however, has 
been questioned, because the kidneys do not normally contain lymphoid tissue. Renal involvement is rare in 
leukemias, and in some leukemias, renal dysfunction is usually found during the blastic crisis. Renal infiltration 
of leukemic cells has been recognized in some patients. In addition, some types of hematological neoplasia are 
associated with severe hypercalcemia that can lead to nephrocalcinosis. Renal involvement is one of the major 
manifestations of multiple myeloma (MM) and is an important cause of renal failure in the elderly. Renal failure 
occurs in more than 50% of MM patients, and is usually caused by the so-called myeloma kidney. Tumor lysis 
syndrome (TLS) is an oncological emergency characterized by a combination of metabolic disorders observed 
at the start of treatment of hematological malignancies. TLS may also be associated with the advancement of 
aggressive lymphomas and leukemias. The syndrome is frequently associated with renal dysfunction. Bone 
marrow transplantation for treatment of selected hematological neoplasms can be complicated by renal failure 
resulting from a variety of causes. Early renal injury most often results from infection and its subsequent treat-
ment. Late renal injury after bone marrow transplantation, characterized by a syndrome similar to the hemolytic 
uremic syndrome, is called bone marrow transplant (BMT) nephropathy. This article reviews the clinical and 
pathological features of renal injury in hematological malignancies. [Hong Kong J Nephrol 2011;13(1):5–18]
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RENAL INVOLVEMENT IN LYMPHOMA
Primary renal lymphoma (PRL) has been reported in the 
medical literature, although its occurrence is rare and 
controversial, the kidney being an extranodal organ [1]. 
The involvement is typically diffuse, bilateral (75% of 
cases), and symmetrical. This presentation is similar in 
both Hodgkin’s lymphoma and non-Hodgkin’s lym-
phoma, although it occurs more often in the latter. PRL 
without evidence of extrarenal spread has also been 
reported [2,3]. The existence of this entity, however, has 
been questioned, because the kidneys do not normally 
contain lymphoid tissue [3–6]. It is generally agreed 
that the criteria for primary extranodal renal lymphoma 
(PRL) should include the following [3–7]:
1. Renal failure as the initial presentation
2. Enlargement of the kidneys without obstruction or 
other organ or nodal involvement
3. Absence of other causes of renal failure
4. Diagnosis made by renal biopsy (Figure 1)
5. Rapid improvement of renal function after therapy
Primary renal lymphoma is a rare disease [8], ac-
counting for only 0.7% of all extranodal lymphomas in 
North America [9] and 0.1% in Japan [10]. A MEDLINE 
search (1980–2008) revealed only 70 cases in the 
English-language literature, of which 28 (43%) had 
bilateral renal involvement [11–26].
Renal involvement in patients with diffuse lym-
phoma has been reported in 34–62% of cases at autopsy 
[6]. In one of the largest series, renal parenchymal in-
volvement was identified in 34% of 696 autopsy cases. 
Of the 142 patients for whom antemortem clinical data 
were available, lymphomatous infiltration was recog-
nized in only 14% prior to death. In contrast, the reported 
incidence of renal involvement by lymphoma has ranged 
between 2.7% and 6.0% based on reviews of computed 
tomography (CT) scans [27]. In patients with newly 
diagnosed non-Hodgkin’s lymphoma (NHL), radio-
logical involvement of the genitourinary tract has been 
reported in as many as 10% of cases [28] (Figure 2). 
The generally higher frequency of lymphomatous infil-
tration of the kidney found in autopsy studies reflects 
the fact that renal involvement is often clinically silent.
Causes and clinical presentation
Most patients with lymphomatous infiltration of the 
kidney have no clinical evidence of renal involvement. 
When present, renal manifestations are usually nonspe-
cific. They may include flank pain, gross hematuria, ab-
dominal distension, and/or a palpable mass. There may 
also be ureteric obstruction by the tumor mass and 
hypertension resulting from renal ischemia due to com-
pression by the tumor. Urate nephropathy, hypercalce-
mia, sepsis, and volume depletion may be the initial 
presentations.
Nephrotic syndrome and nephrotic range proteinuria 
[6,29] may be present. The pathogenesis of paraneo-
plastic glomerulonephritis remains uncertain, although 
autoimmune mechanisms and T-lymphocyte dysfunc-
tion may be important in this respect [30–32]. Immune-
mediated glomerulopathies have been known to be 
associated with both chronic lymphocytic leukemia and 
lymphomas [33–36]. Membranoproliferative glomeru-
lonephritis (MPGN) has been the most commonly re-
ported diagnosis, although minimal change disease, focal 
segmental glomerulosclerosis, membranous glomeru-
lopathy, mesangial proliferative glomerulonephritis, 
immunoglobulin A nephropathy and monoclonal im-
munoglobulin deposit diseases have been reported.
Acute renal failure (ARF) due to lymphomatous in-
filtration of the kidneys is uncommon and is rarely the 
initial manifestation of lymphoma [14,26,29]. Although 
Figure 1. Kidney of a lymphoma patient. Renal tissue is heavily 
infiltrated by lymphoma cells (Jones’ silver stain, 200×).
Figure 2. Kidney of a lymphoma patient. Contrast-enhanced 
computed tomography scan shows bilateral renal masses (arrows) 
of different sizes due to non-Hodgkin’s lymphoma. Associated 
adenopathy is noted.
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the precise mechanisms of ARF in this situation are un-
known, some interesting structure–function relations are 
emerging. Loss of renal function seems to be related to 
both the extent and type of intrarenal tumor infiltration. 
First, renal involvement has to be bilateral and wide-
spread [2,4,7,11]. Second, ARF is much more strongly 
associated with the interstitial type than the intraglo-
merular type of lymphomatous infiltration.
Tornroth et al studied 55 patients with renal lymphoma 
diagnosed by percutaneous kidney biopsy [37]. The prin-
cipal indication in 48 (87%) was ARF or nephrotic-range 
proteinuria. Of the 44 patients with interstitial lymphoma, 
39 (88.6%) presented with ARF compared with 5 (45%) 
among the 11 patients with intraglomerular lymphoma. 
All but two cases (95%) of the 39 patients with ARF and 
interstitial lymphoma showed bilateral enlargement of the 
kidneys. In contrast, none of the patients with ARF and 
intraglomerular lymphoma exhibited enlarged kidneys, 
suggesting different mechanisms behind the appearance 
of ARF in these two groups [33]. Finally and most impor-
tantly, in almost all of the patients with ARF due to inter-
stitial lymphoma, renal function, renal size, and histology 
rapidly improved or returned to normal in response to 
chemotherapy and/or radiotherapy [7,30].
Treatment
The response of renal failure associated with lym-
phomatous infiltration of the kidney to chemotherapy 
and/or radiotherapy is generally good [7,30]. In the 
series reported by Glicklich et al [22], 14 patients were 
treated with various chemotherapeutic regimens. Six of 
them also underwent irradiation limited to the kidneys. 
Three other patients were treated with kidney irradiation 
alone. With these various therapeutic modalities, 11 
patients achieved a serum creatinine concentration of 
< 176.8 μmol/L after therapy. Improvement of renal 
function was often dramatic, with serum creatinine 
concentrations returning to normal 1–4 weeks after 
institution of therapy. The decrease in kidney size to 
normal paralleled the improvement in renal function.
Information on the treatment of immunologically 
mediated glomerular diseases, such as NHL, is limited. 
Little is clear regarding the effects of treatment on the 
progression of these diseases. Moulin et al [34] reported 
one patient with NHL who developed complete remis-
sion of MPGN after treatment with chlorambucil, and 
a second patient who showed significant improvement 
after treatment with MOPP (nitrogen mustard, vincris-
tine, procarbazine and prednisone). Strokes et al [36] 
described a patient with low-grade B-cell lymphoma 
and MPGN who responded to treatment with oral pred-
nisone with improved renal function and diminution of 
proteinuria. Alshayeb and Wall [38] reported a patient 
with NHL associated with MPGN who had a long-term 
remission of glomerular disease after six cycles of cy-
clophosphamide, vincristine and prednisone. Remission 
of immunologically mediated glomerulopathies associ-
ated with Hodgkin’s lymphoma is usually obtained when 
the lymphoma is cured [39]. A review of the literature 
by Korzets and associates, however, yielded 14 patients 
in whom the course of minimal change nephropathy did 
not parallel that of the lymphoma [40]. The patients 
experienced spontaneous remission, but with minimal 
change in the nephropathy.
When renal replacement therapy is required for es-
tablished ARF, it is generally well tolerated and compli-
cations are rare [41].
RENAL INVOLVEMENT IN LEUKEMIAS
Chronic myelocytic leukemia
The leukemic cells of chronic myelocytic leukemia 
(CML) are minimally invasive, and their proliferation 
is largely confined to hematopoietic tissues, primarily 
the blood, bone marrow, spleen, and liver. During the 
blastic phase, not only these sites, but also a number of 
extramedullary tissues, including the kidneys, may show 
leukemic infiltration [42]. Renal involvement, however, 
is rare with CML [43,44]. Renal dysfunction is usually 
found in the blastic crisis of CML. Renal infiltration by 
leukemic cells has been recognized during autopsy in 
patients who had renal dysfunction, acute tubular necro-
sis, and hypercalcemic nephropathy [44] (Figure 3). Few 
cases of CML associated with nephrotic syndrome have 
been described; one case of CML was complicated with 
minimal change nephrotic syndrome and another with 
proliferative glomerulonephritis [45,46].
Chronic myelomonocytic leukemia
Renal involvement is rare in chronic myelomonocytic 
leukemia (CMML), which might also be considered a 
myelodysplastic syndrome. It was found that four of 
825 patients with CMML had glomerulopathy, display-
ing amyloidosis or extracapillary proliferation, but no 
infiltration of the kidneys by leukemic cells [47]. Only 
Figure 3. Leukemic infiltration of the kidney (PAS, 400×).
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a few cases of CMML with leukemic cell infiltration of 
the kidneys have been reported in the world literature 
[48–50], and among these cases a kidney mass was 
present in only two [48].
Chronic lymphocytic leukemia
At autopsy, up to 90% (range 63–90%) of chronic lym-
phocytic leukemia (CLL) cases have kidney infiltration 
[51–54]. Renal failure is rare, however, with only five 
cases having been reported [55,56]. Despite many po-
tential causes of renal complications, it is obvious that 
glomerulonephritis has rarely been reported [57], with 
only about 42 cases recognized [57–61]. The glomeru-
lopathy in these cases most often revealed the presence 
of CLL. Nephrotic syndrome developed in most patients 
(36/42) and was associated with renal failure in only 
one-third. The most common lesion reported seems to be 
MPGN (35.7%), followed by membranous glomerulo-
nephritis [27,32]. The remaining findings were variable 
and include minimal change disease, focal segmental 
glomerulosclerosis, unclassified proliferative glomeru-
lopathy, immunotactoid glomerulonephritis (Figure 4), 
and amyloidosis. In a review of 17 patients with renal 
failure and CLL, 14 patients had renal failure unrelated 
to their CLL. In the remaining three, one had diffuse 
glomerulonephritis, another had tumor lysis syndrome 
(TLS) after therapy, and the third had associated autoim-
mune hemolytic anemia with renal failure [60].
RENAL INVOLVEMENT IN MULTIPLE MYELOMA
Renal involvement, one of the major manifestations of 
multiple myeloma (MM), is an important cause of renal 
failure in the elderly. Renal failure occurs in more than 
50% of MM patients [62,63] and is usually caused by 
a myeloma kidney (discussed below). The degree of 
renal failure is generally moderate and reversible in up 
to 50% of patients, particularly when it is related to such 
precipitating factors as hypercalcemia [64]. When renal 
failure is present, MM has a poor prognosis [65]. Despite 
its frequency and poor prognostic significance, few 
reports deal with the outcome of patients with MM and 
impaired renal function. Renal diseases associated with 
MM include the following:
1. Light-chain deposition disease (LCDD)
2. Myeloma kidney
3. Acute renal failure
4. Renal tubular dysfunction
5. Hypercalcemia and radiocontrast agents’ effect
6. Plasma cell infiltration (Figure 5)
Light-chain deposition disease
Most of the renal diseases in MM are related to over-
production of monoclonal immunoglobulin light chains. 
The risk for renal dysfunction increases with the amount 
of light chains excreted. The risk increases from 7% in 
patients who excrete < 0.005 g/day to 39% in those who 
excrete > 2 g/day [65,66]. Serum or urinary protein 
electrophoresis is no longer recommended, because of 
its limited sensitivity [67].
In contrast to amyloidosis, the deposits in approxi-
mately 80% of patients with LCDD are composed of 
kappa rather than lambda light chains. The deposits are 
also granular in nature, do not form fibrils or beta-
pleated sheets, do not bind Congo red stain or thioflavin 
T, and are not associated with amyloid P protein. In 
amyloidosis the fibrils are usually derived from the vari-
able region of the light chains, whereas in LCDD it is 
usually the constant region of the immunoglobulin light 
chain that is deposited. This may explain the far brighter 
Figure 4. Immunotactoid glomerulopathy typically shows mesangial 
proliferation or a membranoproliferative pattern by light microscopy, 
as in this case. There is widespread splitting of the glomerular 
basement membrane and increased mesangial matrix, with a 
thickened Bowman’s capsule and adhesions of the tuft to Bowman’s 
capsule (Jones’ silver stain, 400×).
Figure 5. Plasma cell infiltration of the kidney in a patient with 
multiple myeloma (Jones’ silver stain, 400×).
Hong Kong J Nephrol • April 2011 • Vol 13 • No 1 9
 Renal disease in hematological malignancies
immunofluorescent staining for light chains found in 
LCDD than of those found in amyloidosis.
The pathogenesis of the glomerulosclerosis in LCDD 
is not entirely clear, but mesangial cells from patients 
with LCDD produce transforming growth factor-β, 
which acts as an autacoid and promotes these cells to 
produce matrix proteins, such as type IV collagen, 
laminin, and fibronectin. Patients with LCDD are gen-
erally > 45 years of age. Many such patients develop frank 
myeloma, and others clearly have a lymphoplasmacytic 
B cell disease such as lymphoma or Waldenström mac-
roglobulinemia. Even in such patients without an overt 
plasma cell dyscrasia, it is the excessive production of 
abnormal monoclonal light chains that produce the 
disease.
As with amyloidosis, the clinical features vary with 
the location and extent of organ deposition of the mono-
clonal protein. Patients typically have cardiac, neural, 
hepatic, and renal involvement; but other organs such 
as the skin, spleen, thyroid, adrenal, and gastrointestinal 
tract may be involved. Patients with renal involvement 
usually have significant glomerular involvement, and thus 
present with proteinuria. The nephrotic syndrome ap-
pears in as many as one-half of these patients, often ac-
companied by hypertension and renal insufficiency. 
Some patients have greater tubulointerstitial involvement 
and less proteinuria, along with renal insufficiency.
The prognosis for patients with LCDD is uncertain, 
but appears to be better than that for amyloidosis. 
As with amyloidosis, death is often attributed to cardiac 
disease and heart failure or infectious complications [68]. 
In a large series of 63 patients, 65% of the patients de-
veloped myeloma [69]. Of the total 63 patients, 36 de-
veloped uremia and 37 died. Predictors of worse renal 
outcome included increased age and elevated serum 
creatinine at presentation. Predictors of worse patient 
survival included increased age, occurrence of frank 
myeloma, and extrarenal deposition of light chains. 
Although there are few data on dialysis and transplanta-
tion in LCDD, patients appear to fare as well as those 
with amyloidosis. Recurrences within the renal transplant 
have been reported. One trial of seven patients with 
LCDD who received renal transplants found recurrences 
in five of seven within a mean time of < 1 year [70]. Thus, 
suppression of the abnormal paraprotein-producing cell 
clone is crucial prior to renal transplantation.
Myeloma kidney
Myeloma kidney should be suspected in older patients 
who present with unexplained acute or subacute renal 
failure, normal-sized kidneys on ultrasonography evalu-
ation, bland urinary sediment, negative or trace-positive 
Albustix test, and a markedly positive sulfosalicylic acid 
test. Myeloma kidney results when light chains with a 
predilection for cast formation are delivered to the distal 
tubule at a critical concentration. Light chains are filtered 
freely, absorbed by endocytotic receptors, and catabo-
lized in proximal tubular cells [71]. The concentration 
of light chains reaching the distal tubule depends on the 
filtrate concentration, and on the capacity of the proxi-
mal tubule cells to absorb and catabolize them. Any 
reduction in the glomerular filtration rate or proximal 
tubular damage increases distal tubular delivery [72,73]. 
At a critical concentration, light chains aggregate and 
co-precipitate with Tamm-Horsfall proteins to form casts 
that obstruct tubular flow [64] (Figure 6). Hemodialysis 
has been described as a treatment for this disorder. Other 
factors that affect cast formation include the following 
[64,72–74].
1. Distal nephron sodium, chloride, and calcium con-
centrations
2. Tubular flow rate
3. Presence of furosemide or radiocontrast agents [75]
4. Acidity of the urine
5. Concentration of the carbohydrate content of Tamm-
Horsfall glycoprotein [64,67]
The diagnosis is confirmed by demonstrating mono-
clonal immunoglobulins in the serum or urine and 
typical intraluminal cast formation observed in a kidney 
biopsy specimen.
Renal tubular dysfunction
In the proximal tubules, there is accumulation of light 
chains that are resistant to proteolytic degradation. They 
form intracellular crystals and cause tubular dysfunc-
tion. This latter can present as Fanconi’s syndrome, with 
proximal tubular acidosis, aminoaciduria, hypouricemia, 
and phosphate wasting that leads to osteomalacia [76]. 
Proximal cell damage also results in decreased proximal 
clearance of light chains, thereby promoting cast 
formation distally [77].
Figure 6. Close-up of intratubular refractile casts with surrounding 
syncytial giant cell reaction. Note the chronic tubulointerstitial 
nephritis and fibrosis, characteristic of myeloma cast nephropathy 
(PAS, 400×).
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About 15% of patients with MM are hypercalcemic, 
with a serum calcium concentration > 2.75 mmol/L at 
diagnosis. Hypercalcemia contributes to renal failure by 
causing vasoconstriction, inducing hypovolemia through 
nephrogenic diabetes insipidus, and intratubular calcium 
deposition [78].
In patients with MM, the incidence of ARF caused 
by the use of radiocontrast agents ranges from 0.6% 
to 1.25% [79]. Contrast medium is thought to bind to 
intratubular proteins, causing them to precipitate and 
obstruct tubular flow. To prevent contrast nephrotoxicity, 
patients with MM must be well hydrated, and use of 
N-acetylcysteine should be considered [79,80].
Plasma cell infiltration of the kidney is seen in 
MM but is rarely severe enough to cause renal dys-
function [81].
Therapy of MM
Although some patients with MM do not require treat-
ment, oncology referral is recommended in all cases 
(Figure 7). Patients with smoldering (asymptomatic) MM 
should not undergo treatment, as current research shows 
that starting active therapy for people with no symptoms 
does not improve survival [82]. Careful follow-up, 
however, is recommended. A systematic review by He 
et al demonstrated a reduction in vertebral compression 
and time to progression with early systemic treatment 
for asymptomatic patients, but their study also revealed 
an increase in acute leukemia in the early-treatment 
group [83]. An important study by Dimopoulos and as-
sociates that evaluated the risk of disease progression in 
asymptomatic subjects with MM showed that the pa-
tients did not benefit from early treatment, and delayed 
treatment did not affect the efficacy of therapy in terms 
of survival [84].
Chemotherapy and bone marrow transplantation
Initial treatment of MM depends on the patient’s age and 
co-morbidities. In recent years, high-dose chemotherapy 
with hematopoietic stem cell transplantation has become 
the preferred treatment for patients under the age of 
65 years. Prior to stem cell transplantation, these patients 
are given an initial course of induction chemotherapy. 
The most common induction regimens used today are 
thalidomide–dexamethasone, bortezomib-based regimens, 
and lenalidomide–dexamethasone [85].
Autologous stem cell transplantation—transplanta-
tion of a patient’s own stem cells after chemotherapy—
is the most common type of stem cell transplantation for 
MM. It is not curative, but does prolong overall survival. 
Allogeneic stem cell transplantation—transplantation of 
a healthy person’s stem cells into the affected patient—
has the potential for cure, but is available to only a small 
percentage of patients [86]. Furthermore, there is a 
5%–10% treatment-associated mortality rate.
Patients over age 65 years and those with significant 
concurrent illness often cannot tolerate stem cell trans-
plantation. For these patients, the standard of care has 
been chemotherapy with melphalan and prednisone. 
Recent studies among this population [87,88] suggest 
improved outcomes with new chemotherapy regimens. 
Treatment with bortezomib, melphalan, and prednisone 
produced an estimated overall survival of 83% at 30 
months [87]; lenalidomide plus low-dose dexametha-
sone produced 82% survival at 2 years; and melphalan, 
prednisone, and lenalidomide produced 90% survival 
at 2 years. In other trials, lenalidomide plus high-dose 
dexamethasone proved to be superior to high-dose dexa-
methasone alone as treatment for newly diagnosed MM 
[88–90]. One study [91] looked at melphalan and predni-
sone plus thalidomide versus melphalan and prednisone 
Multiple myeloma
Young, newly diagnosed, ET
Bortezomib + Adriamycin +
Dexamethasone
Bortezomib + LD (or TD) +
High dose dexamethasone
Melphalan + Prednisone +
LD (or TD)
Newly diagnosed NET
Stem cell transplantationStem cell transplantation
Resistance or relapse
Add bortezomib
SymptomaticAsymptomatic
No treatment
High risk, ET
Figure 7. Approach to the treatment of newly diagnosed multiple myeloma. ET = eligible for bone marrow transplantation; NET = not 
eligible for bone marrow transplantation; LD = lenalidomide; TD = thalidomide.
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versus VAD (vincristine, adriamycin, dexamethasone) 
induction, followed by high-dose melphalan and autolo-
gous stem cell transplantation in patients 65–75 years 
of age. The complete response rate was significantly 
better in the melphalan and prednisone plus thalidomide 
arm than in the melphalan and prednisone arm [91]. 
Melphalan and prednisone plus thalidomide is now 
recommended as first-line treatment. Melphalan and 
prednisone plus lenalidomide have also shown promise 
[91]. Other studies confirmed the superiority of adding 
thalidomide for prolonging survival in elderly, newly di-
agnosed patients with MM. Similar results were obtained 
with bortezomib [92–94].
Bisphosphonates and erythropoietin
Adjunctive therapy for MM includes radiation therapy 
to target areas of pain or an impending or existing patho-
logical fracture. Bisphosphonates have a role in the 
secondary prevention of bony complications in MM, 
including hypercalcemia, pathological fracture, and 
spinal cord compression [95–98].
The American Society of Clinical Oncology (ASCO) 
issued a clinical practice guideline governing bisphos-
phonate therapy for MM patients who have lytic destruc-
tion of bone or a compression fracture of the spine from 
osteopenia [98]. ASCO recommends intravenous pami-
dronate, 90 mg delivered over at least 2 hours, or zole-
dronic acid, 4 mg delivered over at least 15 minutes 
every 3–4 weeks. Because the risk for osteonecrosis of 
the jaw is 9.5-fold greater with zoledronic acid than with 
pamidronate, patients may prefer pamidronate [97].
Zoledronic acid doses should be reduced in patients 
with preexisting mild to moderate renal impairment 
(estimated creatinine clearance 30–60 mL/min); the drug 
is not recommended for use in patients with severe renal 
impairment [96]. All patients receiving pamidronate or 
zoledronic acid therapy should be screened every 3–6 
months for albuminuria. If unexplained albuminuria 
(> 500 mg/24 hr) is found, ASCO recommends discon-
tinuing the drug until the renal problems resolve [96,98].
Erythropoietin may ameliorate anemia resulting from 
either MM alone or from chemotherapy. It has been 
shown to improve quality of life [99,100]. In addition, one 
study demonstrated a survival advantage with the use 
of erythropoietin in patients with MM [101].
Treatment of renal complications
Renal failure in MM patients can be acute (reversible) or 
chronic (irreversible). ARF typically resolves when the 
calcium and paraprotein levels are brought under con-
trol. Treatment of chronic renal failure (CRF) depends on 
the type of renal failure and may involve dialysis. Hydra-
tion (to maintain a urine output of > 3 L/day), manage-
ment of hypercalcemia, and avoidance of nephrotoxins 
(e.g. intravenous contrast medium, antibiotics) are also key 
factors. Ludwig et al suggested that bortezomib-based 
therapy can restore renal function in MM patients with 
renal failure [102]. Bortezomib, however, has many ad-
verse effects, including neuropathy, hypotension, and 
thrombocytopenia. Varicella zoster virus activation occurs 
in 10–60% of patients with MM treated with bortezomib. 
Antiviral prophylaxis (e.g. acyclovir 400 mg daily) has 
been found effective for preventing this activation [103]. 
In addition, the exact timing of bortezomib administra-
tion in the treatment plan of MM patients is still evolving 
through ongoing research.
In an attempt to improve outcomes, direct removal 
of free light chains (FLCs) by plasma exchange has been 
studied [104–108]. A randomized controlled trial of 97 
MM patients with ARF, however, failed to demonstrate 
any clinical benefit [107]. In that study, renal biopsies 
were not reported, serum FLC concentrations were not 
quantified, and most of the patients were not dialysis-
dependent at presentation. Furthermore, plasma ex-
change does not result in sustained reductions in serum 
FLC concentrations, as demonstrated by both clinical 
observations [107] and mathematical modeling [109]. 
Leung et al demonstrated that patients with cast nephro-
pathy are more likely to recover renal function if a 50% 
decrease in serum FLC concentrations is achieved [110]. 
However, they failed to demonstrate any relation between 
the amount of plasma exchange and the degree of reduc-
tion in FLC concentrations or the renal response.
To provide an alternative approach to plasma ex-
change for direct FLC removal, Hutchison and associ-
ates [111] assessed the utility of extended hemodialysis 
(HD), using a high-cutoff (HCO) dialyzer. Detailed 
mathematical modeling showed HCO-HD to be far more 
effective than plasma exchange for FLC removal. In 
their pilot study, induction chemotherapy in combination 
with extended treatment by HCO-HD resulted in sus-
tained reductions in serum FLC concentrations in most 
of their patients. These patients subsequently became 
independent of dialysis. The authors concluded that with 
dialysis-dependent ARF secondary to myeloma kidney, 
patients who undergo uninterrupted chemotherapy and 
extended HCO-HD are more likely to sustain reductions 
in serum FLC concentrations and to recover independent 
renal function. Resolution of cast nephropathy by HCO-
HD has been also supported by the report of Basnayake 
and colleagues [112].
TUMOR LYSIS SYNDROME AND THE KIDNEY
Tumor lysis syndrome (TLS) is an oncological emergency 
characterized by a combination of metabolic disorders 
observed at the start of cancer treatment, or with the 
advancement of an aggressive malignancy. The syndrome 
is frequently associated with renal dysfunction, cardiac 
and skeletal manifestations, and gastrointestinal se-
quelae. TLS occurs with malignancies that are highly 
I.S. Abdul-Rahman
12 Hong Kong J Nephrol • April 2011 • Vol 13 • No 1
proliferative and have large tumor burdens, such as 
lymphomas and leukemias [113–118]. Metabolic ab-
normalities include hyperphosphatemia, hyperkalemia, 
hyperuricemia, and/or hypocalcemia. Renal dysfunction 
usually accompanies TLS. Often, hyperuricemia (gen-
erally, a uric acid level ≥ 476 μmol/L) is a hallmark 
finding of TLS [113,116–118]. Adverse sequelae of TLS 
can precipitate life-threatening events, and if left un-
treated can lead to death.
The prevalence of TLS varies among the hemato-
logical malignancies, and treatment-sensitive tumors, 
such as acute lymphocytic leukemia and Burkitt’s lym-
phoma, are associated with higher frequencies of TLS 
[114,115]. In studies on patients with intermediate- or 
high-grade NHL, abnormal laboratory results were more 
dramatic than the symptomatic clinical syndrome itself 
[113–115]. Silent laboratory evidence of TLS was seen 
in 70% of children undergoing induction chemotherapy, 
whereas significant symptomatic TLS occurred in only 
3% [117]. As advances are made in the treatment of 
hematological malignancies, the incidence of TLS may 
increase [119].
Metabolic abnormalities and consequences
Hyperkalemia may appear 6–72 hours after the initiation 
of chemotherapy [113–115] and is the most serious mani-
festation of TLS. Hyperkalemia must be corrected rapidly 
before potentially lethal ventricular arrhythmias occur.
Hyperphosphatemia usually develops 24–48 hours 
following initiation of chemotherapy [113–115,119]. 
Calcium phosphate can precipitate when the solubility 
product of calcium and phosphate is exceeded, possibly 
leading to hypocalcemia. Muscle cramps, tetany, cardiac 
arrhythmias, and seizures can result.
In patients with myeloproliferative diseases or he-
matopoietic malignancies, nucleic acids are catabolized 
as a result of increased turnover of malignant cell popu-
lations. This results in an increase in purine metabolism, 
leading to hyperuricemia [118], which is usually apparent 
48–72 hours following initiation of treatment [113,114]. 
As a consequence of the hyperuricemia, renal insuffi-
ciency develops when urine becomes supersaturated with 
uric acid, and crystals of uric acid form in the renal tu-
bules and distal collecting system [115,120]. Despite 
management of metabolic abnormalities to reduce the 
risk of renal failure, 25% of children with advanced-stage 
Burkitt’s lymphoma and B-cell acute lymphoblastic leu-
kemia still experience ARF secondary to severe hyper-
uricemia at the onset of chemotherapy [111,117]. In 
patients with TLS, the high uric acid load and hyperphos-
phatemia may overwhelm the ability of the nephron to 
autoregulate. The resultant decline in tubular flow may 
precipitate uric acid, leading to uric acid nephropathy. 
A urine uric acid/creatinine ratio of > 1.0 is suggestive 
of uric acid nephropathy, whereas a ratio of < 0.60–0.75 
suggests renal failure of another etiology [113,114,121].
Patients with hematological malignancies are at 
increased risk of ARF from etiologies other than TLS. 
Acute tubular necrosis should always be considered in 
the differential diagnosis. Patients at risk of TLS are 
also susceptible to other forms of renal injury, owing to 
prolonged periods of hypotension or to exposure to 
nephrotoxic agents, such as antimicrobial agents, che-
motherapy, or contrast media. In addition to the risk of 
nephrocalcinosis, damaged tubule cells may slough off 
into the lumens, resulting in obstructed nephron flow. 
These events further amplify the injury resulting from 
TLS-associated ARF [113,121].
Pathology studies demonstrate deposits of uric acid 
in the distal renal tubular lumens, causing intrarenal 
hydronephrosis. Uric acid crystals also can be seen in 
tubular epithelial cells and the medullary microcircula-
tion [113,114].
Prevention and treatment
The principles of management should address three 
critical areas: hydration, metabolic abnormalities, and 
supportive treatment of renal failure.
Hydration
Aggressive intravenous hydration not only helps correct 
electrolyte disturbances by diluting extracellular fluid, it 
increases intravascular volume. Increased volume en-
hances renal tubular flow, the glomerular filtration rate, 
and urine volume. Ideally, intravenous hydration with 
normal saline should begin 2 days prior to, and continue 
2–3 days after, chemotherapy in high-risk patients 
[113–115,122].
Control of electrolyte disturbances
• Hyperkalemia: The major goals when treating acute 
hyperkalemia are cardiac membrane stabilization, 
intracellular shift of potassium, and reduction of the 
total potassium load. Acute treatment modalities in-
clude intravenous infusion of glucose plus insulin to 
promote redistribution of potassium from the extra-
cellular space to the intracellular space, and intrave-
nous calcium gluconate as cardioprotection for 
potassium levels > 6.5 mmol/L or for those with elec-
trocardiographic alterations. Intravenous hydration 
with alkaline fluid can also increase intracellular 
uptake of potassium. Potassium-wasting diuretics 
must be employed with caution, as they may worsen 
renal precipitation in the volume-contracted patient 
[122]. Long-term therapy such as oral potassium-
exchange resins should be given immediately, be-
cause of the transient effectiveness of acute treatment 
modalities. If these measures fail to control serum 
potassium, hemodialysis should be initiated promptly. 
Dialysis prevents irreversible renal failure and other 
life-threatening complications. Indications for dialysis 
include persistent hyperkalemia or hyperphosphatemia 
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despite treatment, volume overload, uremia, symp-
tomatic hypocalcemia, and hyperuricemia [122]. 
Hemodialysis is preferred over peritoneal dialysis 
or continuous venovenous hemofiltration (CVVH), 
because of better phosphate, potassium, and uric acid 
clearance rates [122,123]. CVVH has been used and 
is effective in correcting electrolyte abnormalities and 
fluid overload [121–124]. Because hyperkalemia can 
recur after dialysis is initiated and because of the high 
phosphate burden in some patients with TLS, elec-
trolyte levels must be monitored frequently and di-
alysis repeated as needed.
• Hyperphosphatemia/hypocalcemia: Hyperphospha-
temia is managed with oral phosphate binders and 
the same intravenous solutions of glucose plus in-
sulin used for control of hyperkalemia. Hyperphos-
phatemia may lead to hypocalcemia, which usually 
resolves as phosphate levels are corrected. In some 
cases, depressed serum 1,25-dihydroxycholecalcif-
erol levels contribute to hypocalcemia. Administra-
tion of calcitriol may correct the calcium levels 
[125]. To avoid metastatic calcifications, however, 
such therapy should not be undertaken until serum 
phosphate levels have normalized.
• Hyperuricemia: The standard treatment for hyper-
uricemia consists of allopurinol, urinary alkaliniza-
tion, and hydration. Allopurinol blocks uric acid 
formation by inhibiting the enzyme xanthine oxidase 
[126,127]. Patients at high risk for TLS still need to 
excrete preexisting uric acid, which is not affected 
by allopurinol. Consequently, a drug that has rapid, 
highly potent uricolytic properties, reduces meta-
bolic morbidity, and can be conveniently integrated 
with the initiation of a chemotherapy regimen would 
be helpful in this situation. Rasburicase is a recom-
binant form of urate oxidase enzyme available for 
this purpose [128–131]. A study in healthy adult male 
volunteers established that single daily intravenous 
doses of rasburicase were well tolerated and led to 
a dramatic decrease in plasma uric acid levels [128]. 
A multicenter Phase II trial of rasburicase in pedi-
atric patients with leukemia and lymphoma (n = 131) 
demonstrated that 100% of patients achieved uric 
acid control with rasburicase at a dose of 0.2 mg/kg, 
despite concomitant intensive chemotherapy [129]. 
Goldman et al. presented a report demonstrating the 
efficacy of rasburicase compared with allopurinol in 
reducing uric acid levels in children with leukemia 
or lymphoma at high risk for developing TLS [132].
RENAL INVOLVEMENT IN BONE MARROW 
TRANSPLANTATION
Bone marrow transplantation (BMT) is an effective treat-
ment for a variety of hematological neoplasms. However, 
side effects in the kidneys have been frequently reported. 
Early during the course of BMT, renal complications 
often result from infection and its treatment. Acute tubu-
lar necrosis may arise as a direct consequence of sepsis, 
hypotension, or therapy with a variety of nephrotoxic 
drugs [133]. A frequent, life-threatening allo-BMT 
complication is ARF requiring dialysis. Some degree 
of acute renal insufficiency developed in ≥ 40% of allo-
BMT patients [134]. Patients are also at higher risk of 
BMT nephropathy, a disorder similar to hemolytic 
uremic syndrome (HUS), which usually occurs during 
the chronic phase after transplantation [134–136]. Al-
lergic interstitial nephritis may evolve from antibiotics 
or allopurinol. Cyclosporine, used early after transplan-
tation to prevent graft-versus-host-disease (GVHD), is 
another agent capable of producing acute or chronic 
nephrotoxicity [136]. The etiology of BMT-associated 
renal failure is thus multifactorial. Risk factors, in ad-
dition to cyclosporine, include veno-occlusive disease, 
age, aminoglycosides, combined use of amphotericin B 
and cyclosporine, amphotericin B alone, elevated pre-
transplant serum creatinine, radiation dose, and GVHD 
[137–143].
BMT nephropathy
The term BMT nephropathy was used by Cohen et al 
to describe this characteristic renal syndrome [138]. An 
incidence ranging from 0.6% to 13.0% has been noted 
in adult patients undergoing BMT [138–140]. Children 
appear to develop the lesion more commonly, with a re-
ported incidence as high as 45% [141]. The pathological 
features of BMT nephropathy are distinct [144–148]. It 
is characterized by prominent mesangiolysis and focal 
aneurysmal capillary dilatation. The endothelial cells are 
swollen, and the subendothelial space is considerably 
widened. The glomerular basement membrane appears 
duplicated. Focal fibrin thrombi may be identified in the 
capillary loops (Figure 8). Electron microscopy reveals 
endothelial injury. The subendothelial space is greatly 
expanded and filled with loose, amorphous, granular 
material consistent with fibrin and newly laid basement 
membrane material (Figure 9).
Two clinical patterns of BMT nephropathy may be 
observed.
• Acute BMT nephropathy characteristically presents 
with an HUS-like picture. Features include micro-
angiopathic hemolytic anemia, thrombocytopenia, 
elevated lactate dehydrogenase, and severe hyperten-
sion with or without congestive heart failure. Renal 
manifestations include a rapid decline in renal func-
tion, significant proteinuria, and microscopic hema-
turia with or without cellular casts [135,136].
• Chronic BMT nephropathy has features that differ 
from those of the acute syndrome. Hypertension 
is only mild to moderate. Hemolytic anemia is 
typically less severe and may be transient [138,139]. 
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All patients, however, tend to have anemia that is out 
of proportion to the level of azotemia [138]. A slower 
decline in renal function, as gauged by the slope of the 
reciprocal of serum creatinine versus time is charac-
teristic [138–140]. In most of these patients, a bipha-
sic pattern of the deterioration of renal function is seen. 
During the first 12–24 months after BMT, renal func-
tion deteriorates steadily. After this phase, it appears 
to stabilize over time, but with no recovery [141–143]. 
Proteinuria, usually > 1 g per 24 hours, and microscopic 
hematuria with or without casts are also present. In-
fection has been noted to precipitate acute exacerba-
tions of this syndrome [143,144,146].
Treatment of BMT nephropathy
Once established, BMT nephropathy is largely unre-
sponsive to all treatment except supportive measures. 
Because the acute form of BMT nephropathy has some 
features of HUS, plasmapheresis has been utilized in 
its treatment. However, the results are generally disap-
pointing [149].
Reduction of the cyclosporine dose or even discon-
tinuation of the drug has been tried in patients who 
develop BMT nephropathy [150]. The vascular toxicity 
of cyclosporine has been thought to play a role in the 
progression of the disease, although it is unlikely to be 
the causative agent. There is no definitive proof that 
discontinuing the drug is beneficial.
Radiation nephropathy can be avoided if the shielded 
area covers one-third of the renal volume [151–153]. 
Renal shielding during post-BMT irradiation is now 
common, but its protective effect is not fully recognized. 
Lawton et al reported that the rate of BMT-associated 
HUS is reduced from 26% to 6% with a decreased 
radiation dose [151,154].
Strategies to control the incidence and severity 
of acute GVHD and veno-occlusive disease
Supportive therapy is important and includes blood 
pressure control to diastolic values of < 90 mmHg, trans-
fusion of blood products, diuretics, and recombinant 
erythropoietin for anemia. These measures appear to 
slow the progression of renal insufficiency [142].
A small number of patients progress to end-stage renal 
disease and require maintenance hemodialysis [142]. 
Transplantation of a kidney from the bone marrow donor 
to the patient with BMT nephropathy and end-stage 
renal disease is an interesting possibility. Because the 
donor marrow presumably has reconstituted the patient’s 
immune system, the kidney theoretically would be well 
tolerated. Successful kidney transplantation using this 
technique has been reported [155,156].
SUMMARY
Malignant lymphomas can affect the kidneys in many 
ways. They may precipitate ARF via ureteral or reno-
vascular obstruction or by direct renal parenchymal 
infiltration. They may also insult renal function via 
paraneoplastic mechanisms. Renal leukemic infiltration 
is usually associated with extramedullary leukemic 
involvement elsewhere. The presence of renal leukemic 
infiltration does not commonly cause renal dysfunction, 
although a few cases of renal failure have been reported.
It is necessary to look for potential renal impairment 
in MM patients. Cast nephropathy with renal failure can 
be aggravated by volume depletion, hypercalcemia, in-
fection, administration of nephrotoxic agents, and pro-
teinuria. Rapid reduction or removal of light chains by 
Figure 8. Bone marrow transplantation nephropathy. The mesangial 
area is expanded with matricial increase or mesangiolysis (arrow). 
There are focal spike formations of the glomerular basement 
membrane (hematoxylin and eosin, 200×).
Figure 9. Electron microscopy of a renal biopsy from a patient with 
BMT nephropathy. The endothelium (single arrowhead) is completely 
stripped from the basement membrane (double arrowheads). 
Electron-lucent material fills the space between the basement 
membrane and the endothelial lining. The caliber of the capillary 
lumen is decreased. Red blood cell fragments are seen in the 
mesangial area (4250×).
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aggressive chemotherapy, extended HCO-HD, and/or 
plasmapheresis may prevent irreversible renal failure.
Tumor lysis syndrome is frequently associated with 
hyperuricemia, hyperkalemia, hyperphosphatemia, and 
hypocalcemia, which may lead to serious complications, 
including acute renal injury.
Bone marrow transplantation is a major therapeutic 
modality for malignant and hematological disorders. 
The procedure, however, is associated with high morbidity 
and mortality rates, including acute kidney injury and 
BMT nephropathy. Recognizing the factors that may cause 
or aggravate these problems, such as nephrotoxic drugs, 
irradiation, and GVHD, may save the kidneys from 
serious damage.
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